ProCE Banner Activity

How I Select Systemic Therapy for Patients With Advanced HCC and Child-Pugh B Cirrhosis

Clinical Thought
Review expert insights into the selection of optimal systemic treatment for patients with advanced HCC and Child-Pugh B liver disease.

Released: November 18, 2020

Expiration: November 17, 2021

Share

Faculty

Mark Yarchoan

Mark Yarchoan, MD

Associate Professor of Medical Oncology
Division of GI Malignancies
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Eisai

Exelixis, Inc.

Genentech, a member of the Roche Group

Lilly

Merck Sharp & Dohme Corp.

Program Director Disclosure

Program Director

Mark Yarchoan, MD

Associate Professor of Medical Oncology
Division of GI Malignancies
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Mark Yarchoan, MD, has disclosed that he has received consulting fees from AstraZeneca, Eisai, Exelixis, and Genentech.